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Abstract
Antibiotic resistance is a major global health concern that requires new therapeutic 
approaches. Furthermore, a lack of narrow spectrum antibiotics on the market  
produces unintended consequences with respect to changes in our microbial make up. 
Phosphonates are  reduced versions of phosphates that possess a C-P bond which is 
more resistant to enzymatic and chemical degradation. The role of phosphonate 
containing macromolecules (e.g. cell surface polysaccharides) remains enigmatic, 
however their presence suggests that they may confer an advantage. The biosynthesis 
of phosphonate-containing macromolecules is unknown, but a pathway is proposed 
involving aLicC type cytidylyltransferase-catalyzed conjugation to a phosphonate 
followed by a LicD type phosphotransferase- catalyzed attachment to a macromolecule. 
This proposed pathway is analogous to the partially characterized phosphocholine (PC) 
tailoring pathway in teichoic acid biosynthesis in Streptococcus pneumoniae. In this 
study, the LicC homolog PngC from Atopobium rimae (Ari-PngC) was purified and its 
activity was compared to LicC from S. pneumoniae (Spn-LicC). Significantly, Ari-PngC 
preferred the phosphonate substrate 2-aminoethylphosphonate (AEP) over PC, and 
vice versa for Spn-LicC. Specifically, the KM and kcat values for Spn-LicC towards PC 
were 0.020 ±0.011 mM and 1.52 ± 0.243 s-1 respectively, yielding kcat/KM of 77.9 M-1 
s-1. In contrast, the KM value for Spn-LicC towards AEP was 0.318 ± 0.126 mM and kcat 
of 0.722 ± 0.053 s-1, yielding kcat/km of 2.27 M-1 s-1 and revealing a 34-fold 
preference for PC. The opposite was seen for Ari-PngC, where AEP gave a KM value of 
0.011 ± 0.001 mM , kcat of 2.72 ± 0.079 s-1 and kcat/KM of 239 M-1 s-1, while  towards PC 
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Ari-PngC yielded specificity constants of 1.67 and 0.74 when modelled by the Michaelis-
Menten or substrate inhibition equation, respectively. Regardless of the correct fit, PngC 
clearly preferred AEP over PC. Overall, these results establish clear substrate selectivity 
of phosphonate versus PC tailoring pathways and set the stage for developing narrow 
spectrum antimicrobials. 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1.1 Human Microbiome and Antibiotic Resistance
The human microbiome describes all microorganisms that reside on and within 
the human body1. The list of microorganisms include bacteria, fungi, and viruses. Every 
individual has a unique microbiome that is acquired from the environment at birth. The 
microbial profile within the microbiome varies with gender, diet, climate, age and 
hygiene1. Microorganisms within the microbiome have been studied to determine their 
interaction with human cells and the benefit or harm they might bring to it. 
Microorganisms, or microbes have been long viewed as things to be gotten rid of, but as 
researches learn more about microbes, they have discovered the importance of 
microbes within the body. Although microbes are important in maintaining a healthy 
body, imbalances to microbial populations can give rise to opportunistic bacteria which 
can lead to disease1. 
The discovery of antibiotics to treat bacterial infections have dramatically 
changed human health, and many once deadly infections are now curable3. Yet, there 
has been a rise in bacteria that are no longer effectively killed by antibiotics3,4. These 
bacteria are known as antibiotic resistant, and are a growing problem in medicine 
around the world. It has been estimated that more than 18,000 hospitalized patients in 
Canada acquire antimicrobial resistance infections3,4,5.. There is also a seven-fold 
increase in the incidence of Vancomycin resistant Enterococci infections between 
2007-2012 in Canada alone3. Not only is antibiotic resistance an issue that threatens 
the human health, it is also the lack of narrow spectrum antibiotics available in the 
market4. Broad spectrum antibiotics disrupt the human microbiota because not only do 
they kill harmful bacteria, they also kill the surrounding non harmful bacteria. This allows 
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for bacteria to have an increased selective pressure to develop resistance. New 
solutions are ungently needed to counteract this loss in antimicrobial efficacy4.
1.2 Phosphorus Containing Compounds
Phosphorus is essential to all living organisms as primary constituent of DNA , 
RNA and ATP6. It is also a key structural component of phospholipids, phosphoproteins, 
phosphorylated exopolysaccharides and numerous metabolites. In addition, phosphorus 
provides buffering capacity, impacts the solubility of organic molecules and can provide 
a high concentration of negative charge within a given molecular dimension6. 
Phosphorus predominantly exists in the most oxidized state (+5 valence) in the form of 
inorganic phosphate, phosphate esters and phosphoanhydrides8. However, there is a 
naturally occurring phosphorus compounds called phosphonates which are found in a 
+3 valence state8. In the recent years, there has been a growth in literature on this 
group of less studied phosphorus compounds. Phosphonates are a chemically stable 
group of compounds containing a direct carbon-phosphorus (C-P) bond7. Since their 
relatively recent discovery of the first naturally occurring phosphonate, 2-
aminoethylphosphonic acid (AEP), in the acid hydrolysate of rumen protozoan in 1959, 
C-P compounds have been identified in a number of bacteria, archaea, and 
eukaryotes9,10,11. In many living organisms these C-P bond compounds are found as 
constituents of extracytoplasmic macromolecules such as phospholipids, 
phosphonoglycans, glycoproteins and lipids12. 
Studies by several research group showed that 2-AEP and derivatives were 
common constituents in lipids in a number of ciliated protozoa, anemones, corals and 
mollusks. The lipid backbone, where 2-AEP or derivatives is bound, is usually either a 
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ceramide as in sphingophospholipids, or a diacylglycerol as in 
glycerolphosphonolipids13. Other phosphonate head group have also been reported 
such as 1-hydroxy-2-AEP found in a sphingophosphonolipid from Bdellovibrio stolpii 
and N-acyl-AEP and N,N-acylmethyl-AEP found in a sphingophosphonolipid from 
Corbicula sandai14. 
Phosphate is a common modification of polysaccharides, but phosphonate 
containing polysaccharide examples are not very common. A phosphonate containing 
polysaccharide or a phosphonoglycan was initially isolated from the plasma membrane 
of the soil amoeba Acanthamoeba castellanii and was shown to be a 
lipopshosphonoglycan15. Among bacteria, Bacteroides fragilis NCTC 9343 produces a 
capsular polysaccharide complex (CPC), (See Figure 1) which is directly involved in 
abscess formation in animal models16. A capsular polysaccharide has also been isolated 
from the outer membrane of the luminal bacterium Fibrobacter succinogenes S8517. 
Figure 1. Phosphonate containing macromolecules isolated. Some examples include 
the phosphonolipid ceramide -AEP from Pythium prolatum, the capsular polysaccharide 
B (PBS) from Bacteroides fragilis and an exopolysaccharide from Fibrobacter 
succinogenes16,17 
The most striking example of phosphonoglycan occurrence is in the freshly laid egg 
masses of fresh water snail Helisoma, where almost 85% of the phosphorus is in the 
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form of AEP and another unknown phosphonate linked to carbohydrates18. 
Phosphonates are now known to be produced by many primitive life forms, in which 
they are normally found as a side group on exopolysaccharides and as a feature of the 
glycan decoration present on glycoproteins.
Sample of phosphonates have been discovered in different sites and depths in 
the Pacific Ocean, Atlantic Ocean and the North Sea, suggesting their importance in the 
marine environment. Although phosphate esters represent about 75% of dissolved 
organic phosphorous in marine environments, phosphonates comprise the remaining 
25%19,20,21 Overall, phosphonates are an important sub-class of phosphorus that may 
play a critical role in phosphorus metabolism. In addition, the ability to synthesize 
phosphonates is present and relative common among microbes in both marine and 
terrestrial environments21. 
The biological function of phosphonate containing macromolecules remains 
puzzling but their presence suggests that they may confer an advantage. There is 
evidence suggesting that the more stable C-P bond may allow cell surface 
macromolecules to persist in challenging host cell environments. Despite the unclear 
role in virulence and host survival for phosphonate containing macromolecules the 
potential roles for these hydrolytically stable molecules need to be further studied. 
1.3 Properties and Types of Phosphonates
The defining structural motif of phosphonate natural products are the carbon-
phosphorus bond. The significant feature of phosphonates is the thermal and chemical 
stability of the C-P bond. Although the C-P bind is weaker than the carbon - oxygen 
phosphorus bond , the departing alkoxide of the latter is a better leaving group than the 
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carbanion of the former in a hydrolysis reaction7. Phosphonates are relatively inert and 
more persistent in threatening environments. This includes exposure to hydrolytic 
enzymes, phosphorus limited surroundings and chemical treatments such as boiling 
acids and bases22. Some phosphonates act as potent enzyme inhibitors because they 
are structural mimics of phosphate esters, carboxylic acids ad tetrahedral intermediates 
and can compete with the latter for binding to enzyme active sites12,22. For instance, 
proteolysis is an important form of cellular regulation, in which peptide cleavage occurs 
at the carboxyl side of targeted amino acids in order to break proteins down in living 
organisms. C-P inhibitors are structurally similar and possess higher affinity to enzyme 
active sites than these phosphate esters and carboxylic acids, allowing them to interfere 
with these cellular processes12. Given the ubiquitous roles of phosphorylated 
intermediates and carboxylates in cellular biology, C-P bond containing compounds 
could potentially target a wide variety of cellular pathways12.
To date, there are approximately 30 known natural C-P compounds making them 
an under explored area of research despite the impressive range of biological activities 
exhibited by these molecules12,22. C-P compounds are known to play a key role in 
metabolic and signalling pathway and possess antibacterial, antiviral, anti parasitic and 
herbicidal properties11. Additionally, enzymes found in their metabolic pathways are 
involved in the production of a number of critical natural products (see Figure 2). These 
include the approved antibiotics fosfomycin, dehydrophos, and plumbemycin; the widely 
used herbicides phosphinothricin tripeptide (PTT) and phosphonitricin; the clinical 
candidates for the treatment of malaria, FR-90098 and fosmidomycin; and 
antihypertensive peptides such as I5B2 (identical with K-4) and K-2622. 
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Figure 2.  Overview of synthesis of natural products that possess a C-P bond and show 
antibacterial, antimalarial and herbicidal properties. The boxed reaction is conserved for 
most known phosphonates22. 
1.4 Phosphonate Biosynthesis
Despite the diversity of natural phosphonates, genetic studies have revealed that 
many of the early steps of these phosphonate biosynthetic reactions are conserved 
across different species and pathways23. This is additionally displayed by similarities in 
biosynthetic gene clusters of various bacterial strains.Initial C-P bond synthesis is 
proposed to occur via intramolecular rearrangement of phosphoenolpyruvate (PEP) to 
form phosphonopyruvate (PnPy) catalyzed by phosphoenolpyruvate mutase (PEP 
mutase)12. Surprisingly, this step is thermodynamically unfavourable, with an equilibrium 
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constant of about 500 in the directional of PEP. The removal of PnPy in this reaction is 
thus important to drive the reaction forward, and this often occurs by decarboxylation of 
PnPy to form phosphonoacetaldehyde (PnAA)12. Several reactions can take to 
transform PnAA, one of which includes transamination to generate 2-
aminoethylphosphonic acid (AEP)22. In alternative biosynthetic pathway, NAD(P)H-
dependent group III alcohol dehydrogenase reduces PnAA to 2-
hydroxyelthyphosphonate (HEP)22. The full biosynthetic reaction pathway can be seen 
in Figure 3.
Figure 3. Proposed biosynthetic pathway for phosphonate small molecules. Labeled 
enzymes in the pathway are as follows: a= PEP mutase, b= PnPy decarboxylase, c= 
AEP transaminase, d= alcohol dehydrogenase
Phylogenetic classification of PEP mutase revealed that there are at least 10 
general groupings of gene clusters capable of generating diverse phosphonates and 
tailored lipids and glycans . In human pathogenic and commensal bacteria, the gene 
clusters typically encode the AEP biosynthetic enzymes ( a, b, and c or d in Fig. 3). 
Interestingly enough, gene clusters also encode genes for cytidylyltransferase and 
phosphotransferase/glycosyltransferase, but the purpose of those genes remains 
unknown. 
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Figure 4. Phosphonate gene clusters from representative bacteria, with genes colour 
coded according to annotation. Lower case letters beside the colour codes in the legend 
correspond to the letters that label the enzymatic steps in Figure 3.
1.5 Choline mechanism in Streptococcus pneumoniae 
Choline metabolism plays a key role in cell separation, transformation, autolysis and 
pathogenicity of Streptococcus pneumoniae25. Choline in the form of phosphocholine 
(P-Cho) is incorporated into the cell wall techie acid (TA) and lipotechoic acid (LTA) 
(Figure 6)26.27.
  
Figure 
5. Teichoic acid of Streptococcus pneumoniae with P-Cho incorporated into it. P-Cho is 
highlighted in the box26. 
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Cell wall phosphocholine also serve as scaffolds for a group of choline-binding proteins 
that are exported from cells and attached to the cell surface by their homologous 
choline-binding domains27. 
The importance of choline in pathogenicity is not confined to S. pneumoniae, but 
also plays a role in other bacteria such as Hemophilus influenzae, Pseudomonas 
aeruginosa and Neisseria gonorrhoaea28 .The pathway for choline metabolism in S. 
pneumoniae consists of a choline transport system, a choline kinase, 
CTP:phosphocholine cytidylyltransferase (CCT) and a choline phosphotransferase that 
transfers P-Cho from CDP-Cho to either lipotechoic acid or lipopolysaccharide28.  The 
existence of this pathway is supported by the detection of choline kinase and CCT 
activity in crude extracts of S. pneumoniae . Bioinformatic analyses have revealed 5 
domains, licA, licB, licC, licD1, and licD228,29. These domains share identity with the H. 
influenzae lic loci. The percent similarity can be seen in Figure 728,29. Hypothesis were 
drawn from bioinformatic analysis and it was concluded that licA corresponds to choline 
kinase28. LicB has several predicted transmembrane domains and is thus thought to be 
a choline transporter28. The hydrophilic licC gene product is a candidate for the CCT 
due to the resemblance of its amino terminus to the amino-terminal 60 residues of NTP 
transferase family members28. Lastly, licD gene is a candidate for the choline 
phosphotransferase28. The licC gene in S. pneumoniae and in H. influenzae are 37% 
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identical and 60% similar28. 
 
Figure 6. Gene cluster of S. pneumoniae and potential function of the gene products 
based on sequence similarity are listed28
It is proposed that choline is acquired from the host and imported to the cell via LicB 
which is a choline transporter. Once in the cell, the choline kinase LicA, phosphorylates 
choline to phosphocholine. Phosphocholine is then CDP conjugated via phosphocholine 
cytidylyltransferase. The CDP conjugated phosphocholine is then attached to a glycan 
by choline phosphotransferase LicD. Figure 8 shows the proposed pathway for choline 
tailoring. Although much is not known about this pathway, gene disruptions of either licC 
or licD have attenuated the virulence of S. pneumoniae in mouse models29,30.
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Figure 7. Proposed pathway for choline tailoring26. 
LicC from S. pneumoniae is a member of the nucleoside triphosphate transferase 
superfamily31, and it catalyzes the transfer of a cytosine monophosphate from CTP to 
phosphocholine, which in turn forms CDP-choline. The enzyme possess a high degree 
of selectivity for phosphocholine and CTP as its natural substrates, and the related 
compounds phosphoethanolamine and ATP as poor substrates31. LicC when recently 
purified, was shown to catalyze cytidylyltransferase reaction. Crystal structure of LicC is 
a monomer, with an active site containing a deep pocket with negative electrostatic 
potential31,33. A bound magnesium balances the negative charges from the amino acid 
residues of Asp107, Glu135, Asp192, Glu216 and Asp21831,33. The amino acid residues 
Asp107 and Glu216 are characteristic of the NTP transferase family which further prove 
that this enzyme resembles the NTP transferases31,33. 
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Figure 8. Active site interactions of LicC with phosphocholine, indicating many important 
active site residues involved in binding. Black dashed lines indicate hydrogen bonds, 
salt bridges, and metal interactions. Green solid line show hydrophobic interactions and 
green dashed lines show π-π and π-cation interactions. PDB: 1JYL31,33
The final tailoring step as seen in Figure 7, involves the attachment of an activated 
phosphocholine conjugate onto a macromolecular scaffold using phosphotransferase or 
glycosyltransferase26,29. The LicD1 and LicD2 enzymes have been hypothesized to act 
as a phosphotransferase in the S. pneumoniae tailoring pathway26,28,29. The loading of 
techoic acids with LicD enzymes appear to be a membrane -associated process, with 
glycolipid anchors and peptidoglycan acting to incorporate the proteins into the cell 
wall26,28,29. Although many of the teichoic acid genes remain to be identifies, the LicD1 
enzymes display significant similarity to other phosphotransferases. 
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Glycosyltransferases are also abundant in gene clusters of S. pneumoniae and varies 
other gene clusters (Figure 4)26,28,29. They catalyze the transfer of sugars, using 
activated donor substrates that contain a substituted phosphate leaving group; acceptor 
substrates make up a diverse group of substrate alcohols such as proteins, lipids, 
nucleic acids, antibiotics, and numerous small molecules. The donor sugar substates 
are most commonly activated nucleoside diphosphate sugars such as UDP and GDP, 
but may also be nucleoside monophosphate sugars such as CMP nuclei acids, lipid 
phosphates and unsubstituted phosphates26. In the absence of LicD homologs, 
glycosyltransferases are seen as principal enzymes in glycan tailoring. The exact 
mechanism involved in LicD enzymology has not been fully characterized.
1.6 Proposed Phosphonate Tailoring Pathway
It is known that choline modifications are involved in virulence, but the role of 
phosphonate modifications remains unknown. The genes responsible for choline 
modifications have been identified, but the genes responsible for phosphonate 
modifications have yet to be identified and biochemically characterized. Interestingly 
enough, phylogenetic analyses of several opportunistic bacteria carrying genes for 
phosphonate biosynthesis (Figure 4), show the presence of cytidylyltransferase and 
glycosyltransferase/phosphotransferase, that share a homology with the genes involved 
in choline modifications. It is hypothesized that in addition to its role as the biosynthetic 
entry point for small molecule bioactive natural products such as the antibiotic 
fosfomycin,  PEP mutase also plays a role in decorating cellular polysaccharides and 
lipids with phosphonate moieties. It is also the introductory enzyme leading to the 
creation of phosphonates (AEP) that may play a significant role in macromolecular 
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tailoring. As previously mentioned, the biological function of phosphonate containing 
macromolecules remains enigmatic, but phosphonate biosynthetic gene clusters are 
widespread in bacteria and suggest that they possess an advantage (Figure 4). For 
example, for pathogens, phosphonate modifications would render cell surface 
macromolecules more resistant to both acid and enzymatic hydrolysis in the 
lysosome24. For commensal obligate anaerobes like Bacteroides that are also 
opportunistic pathogens, phosphonates may be important in the highly anaerobic 
environment of the human distal intestinal lumen24.From this information a biosynthetic 
pathway for macromolecular tailoring can be proposed. It is hypothesized that a small 
molecule phosphonate such as AEP is attached to macromolecules such as 
polysaccharides in a two step process (Figure 5). The first step is the activation of the 
phosphonate (AEP) as a CMP conjugate catalyzed by a cytidylyltransferase. The 
second step is the attachment to a macromolecule nucleophile for example a sugar 
hydroxyl group, catalyzed by a phosphotransferase or glycosyltransferase.
 
Figure 9. Proposed tailoring steps to add a phosphonate to a macromolecule with the 
following enzymes: e, cytidylyltransferase; f, phosphotransferase or glycosyltransferase.
Focusing on the phosphonate tailoring hypothesis, cytidylyltransferase as a homolog for 
LicC may lead to support of the hypothesis that small molecule phosphonate molecules 
such as AEP can be used to create phosphonate containing intermediates, which then 
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are catalyzed by LicD homologs such as phosphotransferases and glycosyltransferases 
in producing macromolecules important for cell metabolism. This proposed mechanism 
is analogous to the choline modification in S. pneumoniae. 
1.7 Phosphonate modifications vs choline modifications
In Figure 4, three different gene clusters of opportunistic bacteria are shown, bacteria 
such as A. rimae and O. uli seem to possess both phosphonate biosynthesis genes, 
and teichoic biosynthesis genes. There are many hypotheses as to why phosphonate 
containing macromolecules may predominate instead of the phosphocholine containing 
macromolecules. One hypothesis is that choline has to be acquired from the host, and 
brought into the cell to be able to be attached to a macromolecule. In the event where 
choline is scarce, the host may utilize PEP, already present in the cell, convert it to a 
phosphonate, and attach it to a macromolecule. Since phosphonates are more resistant 
to degradation and are similar in size and charge to phosphocholine, a bacterial host 
may be able to keep its pathogenicity by swapping choline and utilizing phosphonate 
moieties. Another hypothesis may be that since choline binding proteins are recognized 
by the immune system, phosphonate containing macromolecules can be used to evade 
the immune system. However, as stated earlier the role of phosphonate tailoring 
macromolecules in virulence is unknown. 
1.7 Hypothesis
It is known that phosphocholine is the substrate that is catalyzed by LicC to be added 
onto the teichoic acid, but what is unknown, is if LicC homologs from phosphonate 
containing bacterial strains use AEP to catalyze a similar reaction. A structure for LicC 
from S. pneumoniae has been crystallized and the active site residues are established, 
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however, the similarity of those active site residues to other cytidylyltransferases has not 
been identified.  Based on the information in the literature, few hypotheses can be 
made. The first hypothesis is that the active site residues for all cytidylyltransferase are 
going to be different, to accommodate the substrate that they catalyze. The second 
hypothesis is that LicC homologs in phosphonate pathways will have greater specificity 
for its own substrate. LicC homologs from A. rimae and O. uli will have greater 
specificity for phosphonate substrate AEP, and LicC from S. pneumoniae will have 
greater specificity for phosphocholine. This being said, it is hypothesized that due to the 
nature of LicC genes, they will also have some specificity for substates that may 
resemble their native substrates. 
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1.8 Objectives:
The aims of this project are as follows:
1. Bioinformatic analysis of LicC from S. pneumoniae (Spn-LicC) and PngC from 
Atopobium rimae and Olsenella uli (Ari-PngC and Oul-PngC)
2. Functional Characterization of Spn-LicC and Ari-PngC. 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2. Materials and Methods
2.1 Materials Used
2.1.1 Cloning, Expression and Purification
The Atopobium rimae gDNA was purchased from Cedarlane Labs (Burlington, ON). 
Olsenella uli gDNA was purchased from Biomatik (Cambridge, ON). Synthetic genes for 
O. and A. rimae were purchased from Bio Basic (Markham, ON). Primers were 
purchased from Integrated DNA Technologies (Coralville, IA). PCR buffers and 
polymerases were purchased from Bio Basic (Markham, ON). A C1000 Touch Thermal 
Cycler was purchased from BioRad (Mississauga, ON). Wizard SV Gel and PCR Clean 
-Up System were purchased was purchased from Promega (Madison, WI). Agarose gel 
electrophoresis was performed using a gel apparatus and power source from VWR 
( Mississauga, ON). A Gel Doc EZ imager was used for gel imaging and purchased from 
BioRad ( Mississauga, ON). The PureYield Plasmid Miniprep system was purchased 
from Promega (Madison, WI). DNA sequencingg was completed at the Hospital for Sick 
Children at the Centre for Applied Genomics (Toronto, ON). The Gem T-Easy Vector 
System was purchased from Promega (Madison, WI). Escherichia coli DH5a and BL21 
were purchased from Novagen (Madison, WI). The pET29 vector used for cloning was 
purchased from Novagen (Madison, WI). NdeI and XhoI restriction enzymes were 
purchased from ThermoFisher Scientific (Waltham, MA). The Heroes Multifuge X1R 
centrifuge was purchased from ThermoFisher Scientific (Waltham, MA). High speed 
centrifuge tubes and low speed 500 mL tubes were purchased from ThermoFisher 
Scientific (Waltham, MA). The Q-Sonica Q125 sonic processor was used for sonications 
(Newton, CT). Ultracentrifugal devices were purchased from Pall Corporations (Port 
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Washington, NY). PD-10 columns were purchased from BioRad (Mississauga, ON).  
SDS-PAGE gels were cast using TGX Stain Free FastCast Acrylamide Kit 12% 
purchased from Bio Rad (Mississauga, ON). 
2.1.2 MBP-Cloning and Anion Exchange Purification
pMAL vector was purchased from New England Biolabs (Ipswich, MA). XmnI and NotI 
restriction enzyme was purchased from ThermoFischer Scientific (Waltham, MA). 
Primers were purchased from Integrated DNA Technologies ( Coralville, IA). The FPLC 
machine was purchased and Enrich Q Resin column were purchased from Bio-Rad 
(Mississauga, ON).  The DynaLoop-90 was used to inject sample and was purchased 
from Bio-Rad.  Tris and NaCl were purchased from Amresco (Cleveland, OH).
2.1.3 Crystal Tray Set-Up
Crystal Gryphon LCP system and the INTELLI-PLATE 96-2 plate from Art Robins 
Instruments   (Sunnyvale, CA) was used to set up crystal tray trials. Plastic cover slip 
was purchased from VWR (Mississauga, ON). Crystal screen 1&2 and Index were 
purchased from Hampton Research (Aliso Viejo, CA).  Crystal screens MCSG1 and 
MCSG2 were purchased from Anatrace (Maumee, OH). Crystal trays were incubated at 
18 C in a crystallization incubator from Molecular Dimensions (Newmarket, UK). Crystal 
trays were examined under an Olympus SZX16 light microscope (Tokyo, Japan). 
2.1.4 Pyrophosphate Activity Assay
The EnzCheck Pyrophosphate Assay Kit (E-6645) was purchased from ThermoFischer 
Scientific (Waltham, MA). xMark Microplate Absorbance Spectrophotometer was 
purchased from Bio-Rad (Mississauga, ON) and was used to analyze the results.  CTP 
was purchased from ThermoScientific (Waltham, MA) and MgCl2 was purchased from 
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Amresco (Cleveland, OH). Chelax resin was purchased from Sigma Aldrich ( St.Louis, 
MO).
2.2 Methods
2.2.1 Cloning, Expression and Purification
Polymerase Chain Reaction (PCR): Forward and reverse primers were made for pngC 
and pngD genes from A.rimae and O.uli. Primer sequences can be found in Appendix . 
All of the primers included a 6X His-tag. A 100 μL reaction mixture was then made for 
each of the species in order to amplify the gene. The reaction mixture consisted: of 
DMSO, DI water, 10 mM dNTP mixture, 2x Taq buffer, Taq polymerase, forward primer, 
reverse primer, and the species DNA. The reaction mixture was then aliquoted into eight 
separate 10 μL fractions in an 8- strip PCR tube strip. The eight wells were then put into 
a thermal cycler, set to the conditions that can be seen in Appendix.  Each of the wells 
in the PCR tube strip were set to be exposed to a different annealing temperature within 
the thermal cycle in order to determine which temperature in a specific gradient allowed 
for the best amplification of the gene. In cases where a temperature gradient was not 
used and an optimal annealing temperature was already known, the Taq buffer was 
replaced with a 5x Phusion buffer and Phusion polymerase to replace the Taq 
polymerase. These results were checked using gel electrophoresis, as described in the 
next protocol. 
Agarose Gel and Gel Extraction: A 1% agarose gel was made using 0.40 g of lab grade 
agarose, 40 mL of 1X TAE buffer, and 2 μL of 10 mg/mL ethidium bromide. The 
preparation of 1X TAE buffer is listed in Appendix . After solidification of the prepared 
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gel, the 10 μL fractions of the PCR reaction mixtures were mixed with about 2 μL of 
bromophenol blue dye (unless the they were made with the Phusion buffer, which was 
already dyed green). Each was loaded into a separate well in the gel, along with a final 
well of about 5 μL of 1Kb plus ladder. Gels were run at 100 V and 200 mA for about 45 
minutes. Images were analyzed using ImageLab software and the Bio-Rad “Gel Doc EZ 
Imager”. 
Excision of PCR amplifications: Agarose gels were examined under a LabNet UV trans- 
illuminator and desired bands were cut out using a blade. From these excised gel slices, 
the DNA was amplified and extracted using the Promega Wizard SV Gel and PCR 
Clean-Up System. 
Clean-up and addition of an A-tail: Phusion polymerase has exonuclease activity that 
cuts out the overhang of the DNA amplifications. An A-tail was added to the extractions 
in order to create a new overhang that would be required for complementarity of 
residues when performing a ligation. This was done by mixing: 20 μL DNA, 1 μL Taq 
polymerase, 1 μL 10mM dNTP mxture, 2.5 μL 10X Taq buffer, and 1 μL 50mM MgCl2. 
This reaction mixture was then cleaned up using the Promega Wizard SV Gel and PCR 
Clean-Up protocol. The cleaned reaction mixture was then run on a 1% agarose gel to 
ensure that the presence of the appropriately sized DNA bands. 
Cloning into pGEM: The pGEM-T Easy vector was used to clone the amplifications to 
subsequently be used for sequencing. The cleaned gel extract of DNA was ligated into 
 32
the pGEM vector using the following reaction mixture: 3 μL DNA, 1 μL pGEM-T Easy 
vector, 5 μL 2X Rapid Ligation buffer, and 1 μL T4 DNA ligase. Positive controls were 
created by replacing the DNA with 2 μL Promega control DNA, and negative controls 
were created by replacing the DNA with 3 μL sterile water. 
Transformation of recombinant plasmids into E. coli DH5α: E.coli DH5α competent cells 
were prepared as explained in A5 of Appendix A. Aliquots of 150 μL were thawed on ice, 
and then either the ligation reaction mixture or about 2-4 μL of mini-prepped DNA 
directly were added to the thawed competent cells. The negative and positive controls 
were transformed in the same manner as the ligation. The microcentrifuge tubes were 
then left on ice for 20 minutes and then heat shocked for 2 minutes at 42°C. 1 mL of LB 
broth was then added to the mixtures, after which they were sealed tightly and placed in 
a shaker at 37°C for one hour. The transformation mixtures in the tubes were then spun 
down in a microcentrifuge for one minute, and all but 100 μL of the supernatant was 
poured off. The pellet formed was resuspended in the remaining supernatant and plated 
directly on XCI LB-agar plates, containing 100 μg/mL carbenicillin, 0.5 mM IPTG, and 
80 μg/mL X-Gal. Plates were then left to incubate overnight (approximately 12 hours) at 
37°C. Refer to Appendix  for preparation of LB broth and LB-agar plates.  
Preparing plasmids for sequencing: A single colony from the transformation plates were 
picked using a sterile pipette tip and grown in a 3 mL culture containing 6 μL of 
ampicillin. The cultures were left to grow overnight. The PureYield Plasmid Miniprep 
System was used to isolate the recombinant pGEM plasmid that was then digested with 
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NdeI and XhoI using the following mixture: 2 μL DNA, 2 μL10X FastDigest green buffer, 
1 μL NdeI, 1 μL XhoI, and 14 μL nuclease-free water. This mixture was incubated at 37 
°C for about one hour. To confirm the presence of inserts of the correct size, the 
mixtures were run on a 1% agarose gel and imaged, as described previously. The gel 
extraction protocol previously described was used to excise bands of the correct size 
from the digest. Additionally, if a plasmid of the correct size was identified, about 300 ng 
of the recombinant pGEM plasmid was added to sterile water to make a solution 
totalling 7 μL. 
Cloning into pET29: Excised gel bands from the digests were ligated with pET29. 
Preparation of the pET29 construct is referred to in Appendix . The reaction mixture 
contained: about 3 μL pET29, about 5 μL DNA insert, 1 μL 10X Ligase buffer, 1 μL T4 
DNA ligase. The exact amounts of pET29 and DNA insert added were subject to change 
depending on their relative concentrations; the aim was to add about 3X the 
concentration of DNA compared to pET29. A negative control was made by replacing 
the DNA with sterile water. The ligation was refrigerated overnight, or left at room 
temperature for 1 hour. The ligation reaction mixture was then transformed into E.coli 
DH5α competent cells as described above. However, kanamycin LB-agar plates were 
used with 50 μg/mL kanamycin. Cultures were grown from the colony as described 
before and then mini-prepped to prepare the recombinant pET29 plasmids for another 
transformation into E.coli BL21. These cultures were grown with 5 μL of kanamycin per 
mL of LB broth used.
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Inoculation and induction of pET29 plasmids: One 50 mL culture was then grown from a 
single colony with 250 μL of kanamycin and grown to an OD600 of about 0.5. This 
culture was then aliquoted into 4 separate 1L flasks, each with about 10 mL of the 
culture and 5 mL of 10 mg/mL kanamycin. The flasks were then left to shake at 37 °C 
until an OD600 of about 0.2 was reached. At this time, the shaker temperature was 
turned down to about 18 °C and the flasks were left to shake until an OD600 of about 0.5 
was reached. At this time, 1 mL of the culture was removed and then spun down in a 
microcentrifuge for about one minute to collect an uninduced pellet. The culture was 
then induced with 1 mL of 0.1 M IPTG per 1 L of culture. The culture was then left to 
shake at 18 °C overnight, or approximately 12 hours. Before purification, about 500 μL 
of culture was spun down in a microcentrifuge for about one minute to collect an 
induced cells pellet. 
Protein purification: The total of 4 L of culture was spun down in a centrifuge at 5000 
rpm for 10 min at 4 °C. The supernatant was then discarded and the resulting pellets 
were resuspended in cell lysis buffer (50 mM NaPO4, 0.3 M NaCl, pH 7.5), using an 
amount of buffer that was approximately 5% of the original culture volume. Preparation 
of the buffers can be seen in Appendix B. About 0.2 to 2 mg of both lysozyme and 
DNaseI was added to the solution and then kept on ice 20-30 minutes. The solution was 
then sonicated on ice, programmed to six 10 second intervals of sonicating with 50 
seconds intervals of cooling periods. The mixture was then centrifuged at 14,000 rpm 
for 20-30 minutes at 4 °C. 100 μL of the supernatant was then removed and frozen at 
-20 °C to be analyzed later as the “raw extract” sample. The pellet was also poked, and 
a small portion of it was saved and labeled “cell debris”. The supernatant was then 
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collected in one conical tube, and about 1 mL of Ni-NTA slurry was added. The two were 
then mixed and shaken on ice for 10-20 minutes. The solution was then loaded on an 
Econo-Pac chromatography column and the flowthrough was collected and set aside. 
The column was then washed twice with 5 mL of wash buffer (lysis buffer with 20 mM 
imidazole). Each wash was collected and set aside. An elution buffer (lysis buffer with 
250 mM imidazole) was then added to the column, and the elution was collected in an 
ultrafiltration tubes (MWCO 30 kDa). The elution was concentrated by centrifugation at 
5000 rpm for 40 minutes at 4 °C. In the meantime, the “gravity protocol” was started by 
desalting one PD-10 column. This was done by washing it with equilibration buffer (50 
mM NaPO4 buffer at pH 8). The solution present above the filtration membrane was 
added to the PD10 column and allowed to enter the packed bed. The amount of solution 
added to the column was topped up to 3 mL using equilibration buffer. The flow through 
was discarded. Afterward, 4 mL equilibration buffer was added to the PD10 column and 
the eluent was collected in another ultrafiltration tube. The sample was centrifuged at 
4000 rpm for 40 minutes at 4 °C. The sample present above membrane was then flash-
frozen into beads using liquid nitrogen. The beads were then left in a -80 °C freezer in a 
cryotube. 
Purification modifications for LicC genes: Phosphate free buffers such as Tris was used 
for LicC purifications in order to be compatible for the kinetic assay. In addition to 
changing to phosphate free buffers, 2 mM DTT and 20% Ammonium sulfate were added 
to the buffers. The buffers and their preparation can be seen in Appendix . The 
purification protocol was the same as described above. 
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Bradford assay to determine protein concentrations: A Coomassie Blue Bradford 
reagent was prepared, as seen in Appendix . Six vials were prepared as controls for the 
Bradford standard curve. The vials’ contents can be seen in Appendix. Four vials were 
then prepared for the protein samples. One vial was contained 5 μL flowthrough, one 
with 5 μL raw extract, and two for the final eluted sample (one containing 5 μL of sample 
and another with 20 μL of sample). The vials were then topped up with sterile water until 
a total of 100 μL was reached. 5 mL of Bradford reagent was then added to each of the 
vials and they were left to react for about 5  minutes. About 1 mL of the contents from 
each vial was added to separate cuvettes, and their absorbance readings were 
measured using a spectrophotometer. The concentrations were then calculated by 
comparing the results of the standard curve to the absorbance readings of the samples. 
This was done using a template in Excel. 
Analysis of protein expression: Protein samples were run on an SDS-PAGE gel to check 
for protein expression and appropriately sized protein bands. Samples examined: 
uninduced cells, induced cells, raw extract, inclusion bodies, flow through, wash #1, 
wash #2, and the final protein sample. The samples were prepared by adding about 6 
μg of sample to microcentrifuge tubes. The amount of solution to add for each sample 
was determined using the Bradford assay sample concentrations. The solutions were 
topped up to 16 μL using sterile water, and then 4 μL of 5X laemmli blue buffer was 
added to each of the samples. For the cell debris, induced and uninduced cells a pipette 
was used to simply touch the pellets. The pipettes were then dipped into 16 μL of sterile 
water before adding the 5X buffer. All of the samples were then placed in boiling water 
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for about 5 minutes. After cooling, the full 20 μL of each sample were inserted into the 
wells of an SDS-PAGE gel that was prepared using the BioRad TGX Stain-Free 
FastCast Acrylamide Kit, and soaked in 1X SDS-PAGE buffer. An SDS marker was 
inserted into the wells at each end. The SDS-PAGE was run at 100V for about 30 
minutes, and then 200V for about 45 minutes, or until all of the blue dye had run off the 
gels. The gel was then imaged using the Gel Doc EZ Imager and “Stain-Free” protocol 
in ImageLab. Appendix  displays the preparation of the SDS- PAGE buffer and 
molecular weight markers. 
2.2.2 MBP Cloning and Anion Exchange Purification
Cloning a MBP tag: O.uli pngC and pngDwere cloned into pMAL vector to include a 
maltose binding protein (MBP) tag to increase solubility. MBP primers can be seen in 
Appendix. The DNA was amplified, ligated into pGEM T-easy vector and sent out for 
sequencing using the protocols described above. Once sequencing confirmed the 
amplification of the correct insert, the insert was ligated into pMAL vector using XmnI 
and NotI restriction sites. Since the constructs do not have a His-tag, anion exchange 
chromatography was used instead.
Anion Exchange Purification: 
Buffers to be used for anion exchange were prepared as described in Appendix. To 
prepare the FPLC for purification, all of the lines were transferred from an ethanol 
solution into their corresponding buffers. The ethanol was rinsed out of the lines 
beforehand, and then the new solutions or buffers were pulled through the new lines 
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until there was no air present in the lines. Dynaloop-90 was connected to the system, 
and rinse with water, and Buffer A. The anion exchange column, was washed with 
Buffer A, Buffer B and equilibrated with Buffer A. The ChromLab software on the 
computer was connected to the FPLC, and the template for anion exchange was 
chosen. Proteins were cloned into pET29 in the manner described above, and purified 
up until the Raw Extract. Raw Extract was injected into the DynaLoop-90 and was run 
over the anion exchange column. Fractions of 2 mL samples were eluted and collected. 
Eluted fractions were collected, spun down in a centrifuge to concentrate. A Bradford 
assay and SDS-PAGE were performed to determine the concentration, and purity of the 
proteins. 
2.2.3 Crystal Tray Set Up
Preparation of Protein Sample:
Protein samples need to be very pure and concentrated in order to set up crystal trays. 
Protein samples were run over IMAC chromatography followed by anion exchange 
chromatography to achieve the purest form of sample. Protein samples to be used were 
prepared in the same manner as those used to create frozen protein beads. However, 
the protocol is modified starting at the PD-10 column washes. Instead of washing the 
column with equilibration buffer the PD-10 column was washed with 20 mL of Buffer A. 
Buffer A was also used to elute the sample from the PD-10 column. The sample was 
concentrated, and injected into the FPLC for anion exchange. Once anion exchange 
was completed, the fractions were pooled, and concentrated down to a total of atleast 
10 mg. A minimum volume of 100 uL of sample was required. 
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Preliminary crystal tray set-up:
A 96 well tray was used to set up crystal trays. This was done using the Crystal 
Gryphon LPC system. Four different “store bought” crystal trays were used; MCSG 1&2, 
Index, and crystal screen 1+2 were used. Once the crystal trays were set up, plastic 
cover slips were then placed on top of the corresponding wells to seal the wells. The 
sealed wells were left to equilibrate for about 3 days in the 18 C incubator, and then 
analyzed under a light microscope. The tray was analyzed every three to four days for 
results. 
2.2.4. Pyrophosphate Activity Assay
EnzCheck Pyrophosphate Assay Kit was used to determine the activity of LicC and 
PngC . This assay is a coupled assay, where the first part of the reaction uses 
cytidylyltransferase enzyme, and the second part of the reaction uses pyrophosphatase. 
The reaction is measured at 360 nm using UV-Vis Spectrophotometry. The first reaction 
that uses LicC releases pyrophosphate, which then is made into two inorganic 
phosphates by inorganic pyrophosphatase. The inorganic phosphates react with 2-
amino-6-mercapto-7-methylpurine ribonucleoside (MESG) using purine nucleoside 
phosphorylase (PNP) to get ribose 1-phosphate and 2-amino-6-mercapto-7-methyl-
purine, which is then detected at 360 nm (Figure 10). 
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Figure 10. Conversion of 2-amino-6-mercapto-7-methyl-puring ribonucleoside (MESG) to ribose 
1- phosphate and 2-amino-6-mercapto-7-methylpurine using ribonucleoside phosphorylase 
(PNP) where the formation of 2-amino-6-mercapto-7-methylpurine is measured at 360nm. 
Each reaction was kept to a volume of 100 uL and performed in triplicate. Protein 
samples were prepared in the same manner as described above, containing very pure 
samples as frozen beads. The reaction components were split between 2 wells, one 
well contained the substrate and enzyme, while the other well contained CTP. Well 1 
contained 0.5 uL (1U) PNP, 0.5 uL ( 0.03U) IPP, 10 uL (0.2 mM) MESG, 2.5 uL 20X 
reaction buffer, 16 uL (4 mM )CTP, and 20.5 uL of water, making a total of 50 uL. Well 2 
contained 0.5 uL (1U) PNP, 0.5 uL ( 0.03U) IPP, 10 uL (0.2 mM) MESG, 2.5 uL 20X 
reaction buffer, 12 uL (7 mM) MgCl2, enzyme ( depending on concentration of choice), 
substrate (depending on concentration of choice) and H2O to fill to a final volume of 50 
uL. A control with either no enzyme or substrate was made for each trial. To avoid 
pipetting errors, parent mixes were created for Well 1 and Well 2. If for example, 3 
different substrate concentrations were being tested in triplicate, a parent mix would be 
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made with 9 times the amount of components in each well  in a micro centrifuge tube 
and then be aliquoted out into each well. For example, instead of 0.5 uL of PNP, you 
now would add 4.5 uL of PNP into the micro centrifuge tube. In the end, each well would 
get 50 uL of parent mix aliquoted out. Once the parents mix is aliquoted out, the 
separate wells were incubated for 30 mins at room temperature. After 30 mins, well 2 
was combined to well 1, and absorbance was recorded at 360 nm for 30 minutes.The 
kinetic data was analyzed by excel and plotted using the software R. R uses non linear 
regressions, as well as 95% confidence intervals to determine Michaelis-Menten and 
substrate inhibition curves.  
 42
3. Results
3.1 Bioinformatic Analysis
LicC from S.pneumoniae has been crystallized previously and based on the crystal 
structure important residues in the active site were determined. Based on the amino 
acid sequences of Spn-LicC Ari-PngC and Oul-PngC, structures were created in 
Phyre2. Phyre2 is a protein fold recognition sever which uses amino acid sequences to 
predict and analyze protein structure. The structures created by Phyre2 were analyzed 
to see if the active sites of all the cytidylyltransferaseswere similar. The active site of 
Spn-LicCwas overlaid with the predicted structure of Ari-PngC. 
Figure 11. Active sites of Spn-LicC in blue and Ari-PngC in red overlaid. Arrows pointing toward 
important residues that are conserved in both structures.
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From the figure above it can be seen that the active site residues are conserved 
between both LicC genes. The important residues in Spn-LicC such as Glu 216, and 
Asp 107 which are characteristic of this class of enzymes are conserved. As well as 
additional residues such as Trp 136 and Asp 218 are also conserved in Ari-PngC. Since 
the active sites of both of these enzymes resembles each other, it can be concluded 
that both of these enzymes behave in a similar fashion when catalyzing a reaction. 
Figure 12. Active sites of Spn-LicC in blue and Oul-PngC in orange overlaid. Arrows pointing 
toward important residues that are conserved in both structures.
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The important residues Asp 107, Glu 216 and Asp 218 are also conserved in the LicC 
from O. uli. Although Trp 136 is changed to Phe 105 in Oul-PngC, the residues are 
similar in structure and may be involved in the same manner. It can also be concluded 
that Oul-PngC behaves in a similar way as Spn-LicCwhen catalyzing a reaction. 
Although bioinformatic analysis reveals important residues, crystal structures of both 
enzymes will need to be obtained and compared to the crystal structure of LicC from 
S.pneumoniae. 
3.2 Cloning, Protein Expression and Purification 
The genomic DNA for A.rimae and O.uli were purchased and stored according to 
manufacturers suggestions. Primers were created (Appendix ) for the pngC gene for the 
two strains, and PCR was performed according to the conditions in Appendix. The 
results of the PCR were visualized on a 1% agarose gel.
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Figure 13. Taq polymerase PCR of Ari-pngC with an annealing temperature ranging from 50-65 
C. Lanes A1 and Lanes B1 represent the molecular weight ladder. Lanes A2-5 and B2-4 show 
amplicons at the expected size of 850 base pairs (bp).
The amplification was successful with bands showing up around 850 bp which is the 
correct size, but it can be seen that the optimal temperature for annealing is at lower 
temperatures. Since Taq polymerase is more prone to making mistakes and mutations, 
Phusion PCR at an annealing temperature of 56 C was performed. 
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Figure 14. Agarose gel of Phusion PCR of Ari-pngC at 56 C. Lanes 1-2 show the amplicons at 
850 bp’s and lane 3 is the molecular weight ladder. Unlabelled lanes are irrelevant to this 
research.
Phusion PCR gave great success in amplifying pngC. The amplified bands were at the 
correct size of around 800 bp’s which is the expected size of this homolog. Next, the 
bands in the above figure were extracted, and cleaned using the Promega PCR Clean -
Up System. The cleaned up amplicons were run on an agarose gel to confirm the size 
of the amplicons.
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Figure 15. Clean up of Ari-pngCafter PCR, run on 1% agarose gel. Lane 1 shows the amplicon 
at around 850 bp, and lane 2 shows the molecular weight ladder. Unlabelled lanes are irrelevant 
to this research. 
The cleaned up amplicons were indeed the correct size. The next steps were to add an 
Adenine tail to the amplicons, since Phusion polymerase has exonuclease activity that 
cuts out the overhang of the DNA amplifications. An adenine tail is required to create a 
new overhang to perform successful ligation into different pGEM vector. Adenine tail 
was added using the protocol described in materials and methods, and run on a 1% 
agarose gel.   
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Figure 16. Clean up of Ari-pngC after adenine tail addition. Lane 1 shows the product of the 
clean at around 850 bp, and lane 2 shows the molecular weight ladder. Unlabeled lanes are 
irrelevant to this research.
The adenine overhang addition was a success, and the band was approximately around 
800 bp which is the correct size. The amplicon was ligated into pGEM, and transformed 
into DH5a competent cells, plated on ICX plate and placed in the incubator at 37 C 
overnight. A few white colonies were picked, grown and mini-prepped to isolate the 
recombinant pGEM plasmid. To verify that the ligation into pGEM was successful, a 
digest was done using EcoRI restriction enzyme.
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Figure 17. pGEM digest of Ari-pngC using EcoRI restriction enzyme. Lanes 1-3 show the 
digested product at 850 bp and lane 4 shows the molecular weight ladder. Unlabelled lanes are 
irrelevant to this research.
The pGEM digest was a success as seen in Figure 17, the bands are around 800 
bp which is the estimated size of the Ari-pngC. The gene is now ready to be ligated into 
pET29. The Ari-pngC gene was cut out of pGEM using NdeI and XhoI restriction 
enzymes, and ligated into pET29 vector. The ligations were transformed into Dh5a 
competent cells, and incubated at 37 C overnight. Colonies were picked from the Dh5a 
plates, grown overnight in LB, and mini-prepped according to the protocol described 
above. To determine whether Ari-pngC was successfully ligated into pET29, a restriction 
digest was completed using NdeI and XhoI.
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Figure 18. Digests of Ari-pngC-pET29 constructs using restriction enzymes NdeI and XhoI. 
Lanes 1-3 show digested constructs at 850 bp, and lane 4 shows molecular weight ladder. 
Unlabelled lanes are irrelevant to this research. 
Even though the bands are very faint in Figure 18, it is apparent that the digest was 
successful, and that Ari-pngC gene was successfully ligated into pET29. The next step 
was to express and purify Ari-PngC protein. Ari-pngC-pET29 construct was transformed 
into BL21 competent cells, and expressed using IPTG. The construct was purified using 
immobilized metal affinity chromatography, and run on a SDS-PAGE gel to see if the 
correct protein was expressed, and purified. 
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Figure 19. SDS-PAGE for Ari-PngC. Lane 1 and 10 show molecular weight ladder. Lane 2 
shows uninduced fraction, lane 3 shows induced fraction, lane 4 shows raw extract, lane 5 
shows cell debris, lane 6 shows flow through, lane 7 shows wash 1, lane 8 shows wash 2 and 
lane 9 shows pure protein at around 31 kDa.
Ari-PngC was expressed and purified, and can be seen on the SDS PAGE gel at 
around 31 kDa which is the correct size for the gene. It can also be seen from the gel 
that the protein is pure, and can be used for further analysis. After performing a bradford 
assay, the concentration of the gene was 2.4 mg/mL from a 600 mL purification. 
Preliminary crystal trays was set up for Ari-PngC using the MCSG1, MCSG2, 
Crystal screen 1&2, and Index but no hit was obtained. 
The next bacterial strain with LicC and LicD homologs to express and purify was 
O.uli. Instead of cloning from genomic DNA, synthetic genes for Oul-pngC and Oul-
pngD were purchased. These genes can be ligated into pET29 without any additional 
cloning. Both Oul-pngC and Oul-pngD constructs came in a PBK vector that has a 
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kanamycin resistance, and NdeI and XhoI cut sites. A restriction digest with NdeI and 
XhoI was done on Oul-pngC-PBK and Oul-pngD-PBK constructs and run on a 1% 
agarose gel.
Figure 20. Restrict digest of Oul-pngC-PBK and Oul-pngD-PBK constructswith NdeI and XhoI. 
Lane 1 shows the molecular weight ladder. Lane 2 shows digested LicC at 790 bp, and lane 3 
shows digested LicD at 930 bp. Unlabelled lanes are irrelevant to this research.
From the gel it can be seen that Oul-pngC and Oul-pngD constructs are 790 bp and 930 
bp respectively which confirms that they are at a correct size. Both genes were 
extracted from the gel,and cleaned. The cleaned genes were run on a 1% agarose gel 
to confirm the concentration and presence of the band. 
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Figure 21.  Cleaned gel extracts of Oul-PngC and Oul-PngD. Lane 1 shows molecular weight 
ladder. Lane 2 shows cleaned LicC product at 790 bp and lane 3 shows cleaned LicD product at 
930 bp. Unlabelled lanes are irrelevant to this research. 
Both of the genes were cleaned successfully, and were ligated into pET29. The ligations 
were transformed into Dh5a competent cells, grown and mini-prepped. To check if the 
genes were successfully ligated, restriction digests were done with NdeI and XhoI.
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Figure 22. Oul-pngCpET29 and Oul-pngDpET29 construct digests with NdeI and XhoI 
restriction enzymes. Lanes 1-3 show LicC construct digest at 790 bp and Lanes 4-6 show LicD 
construct digest at 930 bp. Lane 7 shows molecular weight ladder.
It can be concluded from Figure 21 that the genes were successfully ligated into pET29. 
The genes were then transformed into BL21 competent cells to be expressed and 
purified using IMAC. The purified genes were run on an SDS -PAGE to see purity of the 
proteins. 
 55
pngC pngD
2,000 bp
1,000
650
300
Figure 23. SDS-PAGE for Oul-PngC. In order from left to right, lane 1 and 9 are molecular 
weight ladders, lane 2 is uninduced fraction, lane 3 is induced fraction, lane 4 is raw extract, 
lane 5 is cell debris, lane 6 is wash 1, lane 7 is wash 2, and lane 8 is final eluted protein. The 
expected size of the protein is around 31 kDa. 
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Figure 24. SDS PAGE for Oul-PngD. In order from left to right, lane 1 is uninduced fraction, lane 
2 is induced fraction, lane 3 is raw extract, lane 4 is cell debris, lane 5 is flow through, lane 6 is 
wash 1, lane 7 is wash 2 and lane 8 is final eluted protein and lane 9 is molecular weight ladder. 
The expected size of the protein is around 31 kDa
It can be seen from the gels above that both Oul-pngC-pET29 and Oul-pngD-pET29 
constructs are expressed but not soluble. Most of the protein can be seen in the cell 
debris which mostly comprises of insoluble fractions. From Bradford assays, the 
concentration of both proteins was 0 mg/mL which further proves that none of the 
proteins were soluble. 
The next steps were to make soluble versions of Oul-PngC and Oul-PngD,  and 
to do this pMAL vector was used. pMAL vector possess a maltose binding protein tags 
which helps solubilize proteins. Primers were made (Appendix) for the pMAL cloning 
with XmnI and NotI cut sites. Phusion PCR was performed with the new primers on Oul-
pngC-pET29 and Oul-pngD-pET29 constructs, to introduce the MBP tag onto the gene. 
The products of PCR were run on a 1% agarose gel.
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Figure 25. Phusion PCR of Oul-pngC and Oul-pngD for pMAL cloning. Gel A shows pngC 
amplicons in lanes 2-9, with molecular weight ladder in lane 1. Gel B shows amplicons of pngD 
in lane 2-9, with molecular weight ladder in lane 1. The expected size pngC is around 790 bp 
and pngD is around 930 bp.
The PCR was successful, and the bands were extracted from the gel and cleaned using 
Promega Wizard Clean Up System. The cleaned up amplicons were run on a 1% 
agarose gel. 
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Figure 26. Gel extract cleans of Oul-pngC and Oul-pngD amplicons. Oul-pngC clean is in lane 2 
at 790 bp and Oul-pngD clean is in lane 3 at 930 bp. Lane 1 shows the molecular weight ladder. 
The amplicons were the correct size, and are ready for the addition of adenine 
overhang to ligate into pGEM. Adenine overhang was added and genes were run on a 
1% agarose gel to confirm size. 
Figure 27. Adenine overhang addition to Oul-pngC and Oul-pngD. Oul-pngC is in lane 2 at 790 
bp and Oul-pngD is in lane 3 at 930 bp. Molecular weight ladder is in lane 1.
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The agarose gel shows the genes to be at the correct size. The genes were then ligated 
into pGEM and sent out for sequencing. The sequencing results came out negative, and 
it was determined that the primers were made incorrectly. New primers were made with 
NdeI and EcoRI as the new cut sites and Phusion PCR was done on Oul-pngC-pET29 
and Oul-pngD-pET29 constructs. PCR was successful, the genes were cleaned, and 
ligated into pGEM successfully. The new constructs were sent out for sequencing and 
the results came out positive. The constructs were cut out of pGEM, and ligated into 
pMAL using NdeI and EcoRI cut sites. The ligations were transformed into Dh5a 
competent cells. Few colonies were picked, grown and mini-prepped. To confirm 
whether the correct inserts were ligated into pMAL successfully, a double digest with 
NdeI and EcoRI was done. 
Figure 28.Double digest of Oul-pngC-pMAL and Oul-pngD-pMAL constructs with NdeI and 
EcoRI. LicC is in lane 2-3 at 790 bp, LicD is in lane 4-5 at 930 bp and molecular weight ladder is 
in lane 1. 
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Since the ligation into pMAL was successful, the next step was to express and purify the 
construct. Both constructs were expressed in 1 L of LB culture and purified using anion 
exchange since pMAL does not have a His-tag. 
Figure 29. FPLC chromatogram of Oul-PngC-pMAL .
Figure 30. FPLC chromatogram of Oul-PngD-pMAL. 
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The protein fractions boxed in Figure 29 and 30 were collected, concentrated and run 
on SDS-PAGE to determine the purity of the proteins. 
Figure 31. SDS-PAGE for Oul-PngCpMAL. In order from left to right, lanes 1 and 10 are 
molecular weight ladder, lane 2 is uninduced fraction, lane 3 is induced fraction, lane 4 is raw 
extract, lane 5 is cell debris, lane 6 is flow through, lane 7 is wash 1, lane 8 is wash 2 and lane 9 
is final eluted protein. The expected size of this construct is approximately 90 kDa.
Figure 32. SDS-PAGE for Oul-PngD-pMAL. In order from left to right, the wells contained the following: 
SDS molecular weight marker, uninduced fraction, induced fraction, raw extract, cellular debris, flow 
through, wash 1, wash 2, final eluted protein and another SDS molecular weight marker.
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Oul-PngC-pMAL and Oul-PngD-pMAL constructs should be around 80 kDa but from 
both gels it can be seen that both the constructs are at around 31 kDa. It seems like the 
MBP tag was not incorporated to the genes properly. Since Ari-PngCwas already 
soluble, it was chosen to be pursued. 
To be able to determine whether Ari-PngC behaves in a similar fashion as the 
Spn-LicC, the licC  gene was cloned and purified. Spn-licC was purchased from 
BioBasic in a pUC57 vector, with NdeI and XhoI cut sites and a kanamycin resistance. 
The gene was cut out of pUC57 vector using NdeI and XhoI restriction enzymes, and 
ligated into pET29 vector using protocols from the methods section. The product of 
ligation was subjected to another restriction digest with NdeI and XhoI restriction 
enzymes to verify the success/failure of the ligation. The digests were run on a 1% 
agarose gel. 
Figure 33. Double digest using NdeI and XhoI of Spn-licC-pET29. Lanes 1 and 10 show 
molecular weight ladder, and lanes 2-9 represent different colonies of the ligated product. 
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It can be seen from Figure 33, that the ligation was successful. The top band represents 
pET29 band which is at the expected size of 5000 bp, and the bottom band represents 
licC gene which is at the expected size of 774 bp. The gene was then purified using 
IMAC, and purified gene was run on a SDS-PAGE gel to determine purity. 
Figure 34. SDS-PAGE gel of Spn-LicC after IMAC purification. In order from left to right, lane 1 
and 10 are molecular weight ladder, lane 2 is uninduced fraction, lane 3 is induced fraction, lane 
4 is raw extract, lane 5 is cell debris, lane 6 is flow through, lane 7 is wash 1, lane 8 is wash 2 
and lane 9 is final eluted protein. The expected size of protein is 31 kDa.
3.3 Pyrophosphate Assay
Having a soluble Spn-LicC and Ari-PngC, the next step was to determine activity of 
those genes for their respective substrates, and each others substrates. To determine 
activity, an EnzCheck Pyrophosphate Assay Kit was used. When the 
cytidylyltransferase enzyme catalyzes the reaction, it releases pyrophosphate which 
through this kit can be detected. The amount of pyrophosphate released will dictate the 
rate at which the cytidylyltransferase can catalyze the reaction. In using this kit, there 
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are several factors to be considered; one is that all the components being used have to 
be phosphate free, second is that calcium inhibits the enzyme and therefore 
components have to be calcium free. Another factor to consider when trying to 
determine the activity of the enzyme, an enzyme-activity test needs to be completed to 
determine at which concentration the enzyme works best. 
The first step of determining the activity of the cytidylyltransferase enzymes was 
to re-purify the proteins using phosphate free buffers. As well as to help with stability, 
DTT and Ammonium sulphate were also added to the buffers (Appendix). Both Spn-
LicC and Ari-PngC were purified using Tris buffer, and run over SDS-PAGE to determine 
purity. 
Figure 35. SDS-PAGE gel of Spn-LicC after IMAC purification with Tris buffer. In order from left 
to right, lane 1 is raw extract, lane 2 is flow through, lane 3 is wash 1, lane 4 is wash 2, lane 5 is 
final eluted protein at around 31 kDa, and lane 6 is molecular weight ladder.
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Figure 36. SDS-PAGE gel of Ari-PngC after IMAC purification with Tris buffers. In order from left 
to right, the wells contained the following: SDS molecular weight marker, cellular debris, raw 
extract, flow through, wash 1, wash 2, final eluted protein and another SDS molecular weight 
marker.
Both Spn-LicC and Ari-PngC are pure and are at the correct sizes on the SDS-PAGE 
gels. The next step was to set up the reactions and determine the activity of enzymes. 
The first to have its activity determined was Spn-LicC. While carrying out the 
experiments, it was observed that as you increased the phosphocholine concentration 
which is the preferred substrate, the rate of reaction decreased. It was discovered that 
phosphocholine is commercially available only as the calcium salt, and it is previously 
established that calcium inhibits this enzyme. A way to overcome that was to use 
Chelax resin to strip any calcium from phosphocholine prior to using it. Methods were 
established and can be found in the Appendix. Once the phosphocholine was clean of 
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any potential calcium, a test run was performed using non chelaxed phosphocholine 
and chelaxed phosphocholine. 
Figure 37. Pyrophosphate release from Spn-LicC enzyme with 5 mM chelaxed and non 
chelaxed phosphocholine. 
From the figure above it can be seen that the absorbance is higher in the chelaxed 
phosphocholine than the non chelaxed phosphocholine. From this test we can conclude 
that the chelax protocol was successful, and the removal of calcium reversed the 
calcium inhibition. 
After preliminary runs of both enzymes, the next step was to determine which 
concentration of enzyme would be best to use with this pyrophosphate assay. An 
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enzyme-activity test was completed, where different concentrations of enzyme were 
used with 0.1 mM substrate. An enzyme activity assay for LicC with 0.1 mM 
phosphocholine included a range of enzyme concentrations of 0.1 nM to 1000 nM. From 
the graph in Figure 38 it can be seen that the rate increases as the enzyme 
concentration decreases, and rate decreases as enzyme concentration increases. This 
can also be seen in the graph in Figure 39, where LicC from A. rimae is tested with 0.1 
mM AEP and range of enzyme concentrations of 0.1 nM to 100 nM. It appears that 
these enzymes may be working in a monomeric and dimeric forms depending on the 
enzyme concentration. 
Figure 38. Spn-LicC activity assay with 0.1 mM phosphocholine and various concentrations of 
enzyme.
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Figure 39. Ari-Png activity assay with 0.1 mM AEP and various concentrations of enzyme.
From these enzyme activity test, 50 nM of enzyme was picked to be used to get full 
kinetic data. This concentration of enzyme was picked because it was in the middle of 
the ranges of enzyme concentrations used, and gave activity that could be easily 
detected and measured.
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Figure 40. Michaelis -Menten fit for Spn-LicC with phosphocholine. 
Figure 41. Residual plot for Spn-LicC with phosphocholine
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Figure 42. Michaelis-Menten fit for Spn-LicC with AEP
Figure 43. Residual plot for Spn-LicC with AEP
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Figure 44. Michaelis -Menten fit for Ari-PngC with AEP
Figure 45. Residual plot for Ari-PngC with AEP
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Figure 46. Michaelis - Menten fit (red)  and substrate inhibition fit (purple) for Ari-PngC with 
phosphocholine.
Figure 47. Residual plot for Ari-PngC with phosphocholine (Michaelis-Menten curve)  
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Figure 48. Residual plot for Ari-PngC with phosphocholine (Substrate inhibition)
Table 1. Summary of kinetic parameters for enzymes
Enzymes Substrate Km (mM) kcat (per 
second)
Ks (mM) kcat/Km      
(/s*mM)
Substrate 
Preference
Ari-PngC PC (MM) 0.026 ± 
0.097
0.344 ± 0.028 N/A 1.67 143 fold for 
AEP 
322 fold for 
AEP 
PC 
(Inhibition)
1.000 ± 
0.826
0.717 ± 0.344 3.99 ± 
3.52
0.74
AEP 0.011 ± 
0.001
2.72 ±
0.079
N/A 239
Spn-LicC PC 0.020 ± 
0.011
1.52 ±
0.243
1.53 ±
0.675
77.9 34 fold for PC
AEP 0.318 ±
0.126
0.722 ±
0.053
N/A 2.27
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4. Discussion:
The  purpose of this project was to functionally characterize cytidylyltransferases 
from A. rimae and O. uli to gain insight into the mechanism behind phosphonate 
containing macromolecules. The first step to characterizing these genes was to use 
bioinformatic tools such as Phyre2 to predict the preliminary structure. Phyre2 
generated predicted structures based on amino acid sequences from the genes.  The 
predicted structures of Oul-PngC and Ari-PngC were compared with the previously 
characterized Spn-LicC. The active site of Spn-LicC was overlaid with the predicted 
active sites of Oul-PngC and Ari-PngC to see the similarities and differences. In Figure 
11, Spn-LicC  in blue is overlaid with Ari-PngC. Important active site residues necessary 
for catalysis in LicC are Asp 107, Glu 226, Asp 218 and Trp 13631,33. In Figure 11, it can 
be seen that all of these important residues are present in the Ari-PngC as well. There 
are however, subtle differences in the active sites such as the distance of the residues 
from each other, which would dictate how well a substrate can bind in the active site to 
be catalyzed efficiently. Active sites of Oul-PngC was also compared with Spn-LicC in 
Figure 12. Important residue Trp 136 is switched to Phe 105, but all the remaining 
important active site residues are conserved. These differences in the active sites point 
to this enzyme having different substrate specificity. 
The second step to characterize these genes was to clone, express and purify 
them to study their activity against various substrates. All three cytidylyltransferase 
genes were cloned and expressed in pET29, but only genes from S. pneumoniae and 
A. rimae were able to be purified successfully. Once these genes were purified, a 
pyrophosphate assay was used to determine their activity. The software R was used to 
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obtained the kinetic parameters. The first step to determining activity was to determine 
at which concentration these enzymes worked best, and to do so an enzyme -activity 
assay was performed. In this assay, different concentrations of enzyme were used with 
0.1 mM of respective substrate and rate was monitored. From Figure 38 and 39 it can 
be seen that at lower concentrations of enzyme the rate of reaction is higher. This was 
an odd behaviour exhibited by the enzymes, however it this type of relationship between 
enzyme concentration and rate is precedented. A well studied example of this type of 
relationship is the D-amino acid oxidase34,35. D-amino acid oxidase exists in an 
equilibrium state of the monomer and dimer at appropriate concentrations; however 
after more analysis it was seen that at lower enzyme concentrations, D-amino acid 
oxidase shifts to favour the monomer state, giving higher rate values34,35. The opposite 
effect was seen with higher enzyme concentrations, where the rate decreased, and the 
equilibrium was shifted to favour the dimer state.34,35. This type of relationship is not 
exclusive to D-amino acid oxidase, but also exists in purine nucleoside phosphorylase36, 
isocitrate dehydrogenase37, UMP/CMP kinase38 and many more.  Although the structure 
of Spn-LicC is classified as a dimer, under these assay conditions, it demonstrates an 
oligomeric properties. This is also observed for Ari-PngC. This type of unorthodox 
relationship is interesting, and poses the question of whether this enzyme has just a 
monomer/dimer form or does it have the capabilities to exists in many oligomeric forms. 
The information obtained from these enzyme- activity assays was used to determine a 
concentration at which kinetic parameters were calculated. The kinetic parameters and 
their summary can be found in Table 1. for both Spn-LicC and Ari-PngC. 
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The first enzyme to be characterized by this pyrophosphate assay was Spn-LicC 
This enzyme has been previously biochemically characterized and in literature has a Km 
ranging from 0.083 mM to 0.39 mM for its substrate phosphocholine, with a kcat ranging 
from 3.0/s to 17.5/s28,31. There is a discrepancy in the values obtained from this assay 
and those available in literature which could be explained by the oligomeric forms of this 
enzyme as mentioned previously. The Km and Kcat for LicC with phosphocholine (PC) 
were 0.020 ± 0.011 mM and 1.52 ± 0.243 /s respectively. Instead of a classic Michaelis 
- Menten curve, our data shows a substrate inhibition curve between LicC and 
phosphocholine, and because of this the Ks value was determined to be 1.53 ± 0.675 
mM. From literature it is known that LicC is strongly inhibited by calcium, and 
phosphocholine when bought commercially is made with calcium. Even though best 
efforts were made to remove calcium from phosphocholine through Chelax, some 
calcium may have been left behind causing LicC to be inhibited at higher concentrations 
of phosphocholine. Further methods will need to be established to measure the calcium 
concentration in phosphocholine before performing enzymatic assays. Another theory to 
support substrate inhibition for LicC with phosphocholine can be modelled to a classic 
substrate inhibition model. Enzyme inhibition is one of the common derivations from 
Michaelis- Menten kinetics, and means that the velocity curve of a reaction rises to 
maximum as substrate concentration increases and then descends either to complete 
inhibitions or to a partial inhibition39. This happens when two substrate molecules bind 
to the enzyme at the active sites and non-catalytic inhibitory sites39. In our case, at 
higher concentrations of phosphocholine, it could be binding to one enzyme active site, 
rather than binding to various different enzyme active sites, causing the velocity of the 
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curve to descend. Having kinetic parameters of LicC with phosphocholine, the next step 
was to see if this enzyme has any specificity for other substrates. The substrate of 
choice was 2-aminoethlyphosphonic acid (AEP) which is the native substrate proposed 
for phosphonate tailoring (Figure 42) . The Km value for LicC with AEP was 0.318 ± 
0.126 mM and kcat of 0.722 ± 0.053 /s. The kinetic parameters for AEP are significantly 
lower than phosphocholine. It was calculated that Spn-LicC has a 34 fold greater 
preference for phosphocholine than AEP. 
The second enzyme to be characterized was Ari-PngC. This enzyme was 
characterized with AEP, its native substrate and phosphocholine to determine substrate 
specificity of the homolog. When tested with AEP, this enzyme exhibits a classic 
Michaelis Menten fit (Figure 44), with with Km value of 0.011 ± 0.001 mM and a kcat of 
2.72 ± 0.079/s. When this enzyme was tested with phosphocholine, which is a similar 
looking substrate to AEP, the data was inconclusive. The data set could be modelled to 
both a classic Michaelis- Menten and a substrate inhibition curve, however the kinetic 
parameters that are modelled to Michaelis Mentin curve are statistically more 
significant. The residual plots for Ari-PngC with phosphocholine show high variability. 
Since phosphocholine was used and we know that Spn-LicC is inhibited by calcium, this 
could be used to explain why it is difficult to determine whether there is a substrate 
inhibition curve or a Michaelis - Menten curve. Comparing the kinetic parameters 
obtained with both substrates, it can be seen that AEP is the preferred substrate of 
choice, with a 143-322 fold greater specificity. 
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From the results obtained in our assay, Spn-LicC had a kcat of 1.52 /s with its 
native substrate phosphocholine, while Ari-PngC has a kcat of 2.72 /s for its native 
substrate AEP. It can be seen that there is a higher turnover number with Ari-PngC from 
the phosphonate biosynthesis pathway than the choline pathway. Phosphonates are 
considered to be ancient molecules and this hypothesis is supported by their presence 
founded on the Murchison meteorite40. A theory to support the observation that Ari-PngC 
found from the phosphonate pathway is more active that Spn-LicC from choline 
pathway, can be attributed to the fact that Spn-LicC could have evolved from Ari-PngC. 
Although this hypothesis is just a hypothesis, more study into phosphonate compounds 
needs to be done, in order to show any evolutionary relationship between these 
enzymes. 
The results of the bioinformatic and kinetic data together prove the hypothesis to 
be valid. After comparing the active sites of cytidylyltransferase genes, it was apparent 
that there were subtle differences in the residues surround the active site, and that 
would be most likely to accommodate different substates based on specificity. This was 
further confirmed by the kinetic data of Spn-LicC and Ari-PngC, where each enzyme 
has a preferred substrate. Spn-LicC greatly preferred phosphocholine as its substrate, 
where as Ari-PngC greatly prefers its substrate AEP. It is hypothesized that 
cytidylyltransferase genes are used to tailor macromolecules with different moieties, 
such as phosphocholine or small molecule phosphonates, which are then loaded onto 
cell wall surfaces. Many antibiotics available in the market target cell wall synthesis, but 
are broad spectrum and destroy microbes that may not be involved in pathogenicity. 
This increases the selective pressure for the pathogens that survive the antibiotic 
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attack, and allows them to replicate to become the dominant type of microbial 
population, hence causing a greater resistance. Since each of the opportunistic bacteria 
studied in this project possesses either phosphonate gene cluster, teichoic acid 
biosynthesis gene cluster or both, antibiotics can be designed to target these pathways. 
From the data presented in this project, it is evident that each cytidylyltransferase gene 
has greater specificity for their native substrate. Using this knowledge, narrow spectrum 
antibiotics can be designed to target specific cytidylyltransferase genes from either 
phosphonate or teichoic acid synthesis pathway. Inhibiting this cytidylyltransferase gene 
would stop macromolecules from being loaded onto cell wall surfaces, and may aid in 
the loss of virulence. This type of antibiotic would be beneficial because it will be very 
narrow spectrum, ensuring that no other microbe is being destroyed, hence removing 
any selective pressure to cause resistance.
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5. Future Directions and Conclusion
Many questions were answered within this project, but many remain unknown. 
Additional experiments need to be performed in order to gain further insight into 
cytidylyltransferase and their function. For example, from enzyme-activity tests of each 
enzyme it was determined that they may have more than just a dimer function. 
Experiments such as dynamic light scattering (DLS) can be completed to confirm if 
these enzyme have more oligomeric forms. In addition to DLS, crystal structure of these 
enzymes need to be solved to determine how exactly the enzyme functions, and what 
within the active site allows for specificity of certain substrates more than others. Lastly, 
it is necessary to determine if the product from enzyme catalysis is what we predict it to 
be. This can be accomplished by HPLC and mass spectrometry. 
In conclusion, there is a urgent need for new antimicrobials to overcome 
antimicrobial resistance. Phosphonates are a class of natural products that have a C-P 
bond that is more resistant to degradation. Phylogenic analyses of opportunistic 
bacteria have revealed a presence of genes necessary for phosphonate biosynthesis, 
as well as genes that are hypothesized to be involved in macromolecular tailoring. The 
genes involved in macromolecular tailoring such as PngC and PngD homolog resemble 
the genes involved in the tailoring of teichoic acids in S. pneumoniae. After further 
bioinformatic analysis it was revealed that Spn-LicC resembles PngC from A. rimae and 
O. uli. It was also revealed through kinetic analyses Spn-LicC has greater specificity for 
phosphocholine, but still has some specificity for AEP, and Ari-PngC has greater 
specificity for AEP but can still catalyze phosphocholine. If these findings are true, then 
this information can be used to design therapeutics that would target the licC locus, 
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which would disrupt the tailoring of macromolecules without harming the surrounding 
environment, and in turn lower any selective pressure on microbes from developing 
resistance. 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Appendix: Additional Information
A1. Vectors
pET29 vector
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pMAL Vector
A2. Primer Sequences
Gene Sequence Tm (C) Restricti
on Sites
Resistance 
Marker
LicC - A.rimae Forward: 5'-
CATATGCATCATCATCACCATCATAGCAGCGG
TGTTGATCTGGGCACCGAAAATCTGTATTTTC
AGAGC 
ATGGCTTGTGTAAAAGGTTCAAATG-3’
Reverse: 5'-CTCGAG 
CTAACTCCTCAAAAGATATACGTAG-3'
F: 68
R: 65
NdeI and 
XhoI
Kanamycin
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A3. Construct Sequences
LicC - S.pneumoniae (pET29) 
Restriction Sites: NdeI and XhoI 
Amino Acid Sequence: 
MGSSHHHHHHSSGLVPRGSHMKEIRVKAIILAAGLGTRLRPLTENTPKALVQVNQKPLI
EYQIEFLKEKGINDIIIIVGYLKEQFDYLKEKYGVRLVFNDKYADYNNFYSLYLVKEELA
NSYVIDADNYLFKNMFRNDLTRSTYFSVYREDCTNEWFLVYGDDYKVQDIIVDSKAGRI
LSGVSFWDAPTAEKIVSFIDKAYASGEFVDLYWDNMVKDNIKELDVYVEELEGNSIYEID
SVQDYRKLEEILKNEN
DNA Sequence: 
CATATGGGTTCTTCTCACCACCACCACCACCACTCTTCTGGTCTGGTTCCGCGTGG
TTCTCACATGAAAGAAATCCGTGTTAAAGCGATCATCCTGGCGGCGGGTCTGGGTA
CCCGTCTGCGTCCGCTGACCGAAAACACCCCGAAAGCGCTGGTTCAGGTTAACCA
GAAACCGCTGATCGAATACCAGATCGAATTCCTGAAAGAAAAAGGTATCAACGACAT
CATCATCATCGTTGGTTACCTGAAAGAACAGTTCGACTACCTGAAAGAAAAATACGG
TGTTCGTCTGGTTTTCAACGACAAATACGCGGACTACAACAACTTCTACTCTCTGTA
CCTGGTTAAAGAAGAACTGGCGAACTCTTACGTTATCGACGCGGACAACTACCTGT
TCAAAAACATGTTCCGTAACGACCTGACCCGTTCTACCTACTTCTCTGTTTACCGTG
AAGACTGCACCAACGAATGGTTCCTGGTTTACGGTGACGACTACAAAGTTCAGGAC
ATCATCGTTGACTCTAAAGCGGGTCGTATCCTGTCTGGTGTTTCTTTCTGGGACGC
GCCGACCGCGGAAAAAATCGTTTCTTTCATCGACAAAGCGTACGCGTCTGGTGAAT
TCGTTGACCTGTACTGGGACAACATGGTTAAAGACAACATCAAAGAACTGGACGTTT
ACGTTGAAGAACTGGAAGGTAACTCTATCTACGAAATCGACTCTGTTCAGGACTACC
GTAAACTGGAAGAAATCCTGAAAAACGAAAACTAACTCGAG
LicC - O.uli 
(MBP)
Forward: 5’-GAAGGATTTC ATG GCA GCA 
GGT CTG GGT AC-3’
Reverse: 5’-GCGGCCG TTA ACC TTC ATC AAT 
ATT GCT ACG-3’
F: 64
R: 64
NotI and 
XmnI
Carbenicillin 
LicD - O. uli 
(MBP)
Forward: 5’-GAAGGATTTC ATG CGT GAA TAT 
GAT GCA GAA AC-3’
Reverse: 5’-GCGGCCG TTA ATA GGC ACC 
AAA ATC CAG AC-3’
F: 64
R: 64
NotI and 
XmnI
Carbenicillin 
Gene Sequence Tm (C) Restricti
on Sites
Resistance 
Marker
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LicC - A. rimae (pET29)
Restriction Sites: NdeI and XhoI
Amino Acid Sequence:
CATATGCATCATCATCACCATCATAGCAGCGGTGTTGATCTGGGCACCGAAAATCTG
TATTTTCAGAGCATGGCTTGTGTAAAAGGTTCAAATGCCGAGAAGACCAATGCGATT
ATAATGGCGGCGGGATTGGGAACGCGCATGGCACCTCTCACCAAAACCACACCTAA
GCCGTTGATTTCGGTCAACGGAACGCCGATGATTGAAACGGTCATCAATGCGCTGG
TTACGGCCGGCGTTGAGAGGATCTCTGTGGTTGTCGGGTATCTCAAAGAGCAGTTT
TGCTATCTTGAGGAGCGCTATCCGGCCGTAGTGCTTGTTGAGAACACGGAGTATTT
GGAGAAGAATAACATCTCATCAATATATGCCGCCGTTGACGTTCTTGAGCAGGGGG
CTACGTTTATTTGCGAGGCTGACCTGGTTATTTCAGATGAGCATATTTTCCAACCACG
GCCTTCTCGGTCGTGCTATTTTGGCCGTAAGTTTTCCGGCCATACGGGCGACTGGG
TGTTTGACCTTGACGATTCGGGAAAGATTGTCCGAATCGGCAAAGGCGGCAGCGAT
ACGTATGCCATGGTGGGACTGTCGTACTTCTCGGCACCGGATGCAAAGCGTTTGGC
ACGGTTTATGCATGATGCCTACAAAGAGACCGGCCACGAGCAGCTCTTTTGGGATG
ATGTGGTGAATAACCATATTGCCGAATTAGATCTTTCAATTCACCCCGTTGAGGCACA
GCAAATTGCGGAGCTTGATAGCGTTGCGGAATTGGCGGCGTTTGACCATGGCTACG
TATATCTTTTGAGGAGTTAG 
DNA Sequence: 
MACVKGSNAEKTNAIIMAAGLGTRMAPLTKTTPKPLISVNGTPMIETVINALVTAGVERI
SVVVGYLKEQFCYLEERYPAVVLVENTEYLEKNNISSIYAAVDVLEQGATFICEADLVIS
DEHIFQPRPSRSCYFGRKFSGHTGDWVFDLDDSGKIVRIGKGGSDTYAMVGLSYFSAP
DAKRLARFMHDAYKETGHEQLFWDDVVNNHIAELDLSIHPVEAQQIAELDSVAELAAFD
HGYVYLLRS
LicC - O. uli (pET29)/ (pMAL)
Restriction Sites (pET29): NdeI and XhoI 
Restriction Sites (pMAL): NotI and XmnI
Amino Acid Sequence:
CATATGCATCATCATCACCATCATAGCAGCGGTGTTGATCTGGGCACCGAAAA
TCTGTATTTTCAGAGCATGGCAGCAGGTCTGGGTACACGTATGGCACCGCTG
ACCCAGATGACCCCGAAACCGCTGATTCGTGTTAATGGCACCCCGATGATTG
AAAGCGTTATTAATGCACTGGAAGCAGCCGGTGTGGCATGTATTTATGTTGTT
GTTGGTTATCTGAAAGATCAGTTCCGCTATCTGGAAGAACGTTATGGTCCGG
TTAAACTGATTGAAAATCCGGAATATCTGAGCAAAAACAACATCAGCAGCATT
TATGCAGCCATTGAAGTTCTGGAACAGGGTGATGCATTTATTTGTGAAGCAGA
TCTGGTTGTTAGCGAAAGCGGTATTTTTAGCGATCTGCCGAGCAAAAGCTGT
TATTTTGGTCGTATGACCGAAGGCTATACAGATGATTGGGCATTTGATCTGGA
TACCACCGGTCGTATTACCCGTGTTGGTAAAGGTGCAGTTAATAGCTATGCAA
TGGTTGGCATCAGCTTTTTCAAAGGTGGTGATGCAGCACATCTGGCACGTTG
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TATTCGTAGCGCATATACCCAAGAAGGTCACGAACGTCTGTTTTGGGATGATA
TTGTGAACCAGCACATCGATGAATTCGATCTGCGTATTCGTCCGGTTCTGGA
AGGTCAGGTTGTGGAACTGGATACAATTGAAGAACTGGCAGCCTTTGATCCG
AGCTATAGCGATCAGCTGCGTAGCAATATTGATGAAGGTTAACTCGAG
DNA Sequence: 
MIESVINALEAAGVACIYVVVGYLKDQFRYLEERYGPVKLIENPEYLSKNNISSIYAAIE
VLEQGDAFICEADLVVSESGIFSDLPSKSCYFGRMTEGYTDDWAFDLDTTGRITRVGK
GAVNSYAMVGISFFKGGDAAHLARCIRSAYTQEGHERLFWDDIVNQHIDEFDLRIRPVL
EGQVVELDTIEELAAFDPSYSDQLRSNIDEG
LicD - O.uli (pMAL)
Restriction Sites: NotI and XmnI
Amino Acid Sequence:
CATATGCATCATCATCACCATCATAGCAGCGGTGTTGATCTGGGCACCGAAAA
TCTGTATTTTCAGAGCATGCGTGAATATGATGCAGAAACCCTGCGTCATGTTC
AGCAGTGTGAACTGAAAATTCTGAAAGATGTTGCCCGTATTTGTGATGGTCA
GGGTCTGACCTATTTTGGTCTGGCAGGCACCGGTATTGGTGCAATTCGTCAT
AAAGGTTTTATTCCGTGGGATGATGATATTGATATTGGTATGCCTGCACGTGAT
CTGGAACAGCTGGTTAAAATCATTCGTGAAGAACATGCAGGCACCTATGATG
TTATTAACGCCGATATCGATAGCAATTATCCGCTGGCAACCACCCGTATTATGC
TGAAAGGCACCCAGTTTTGTGAAGAAACACTGAGCGAACTGCCGCTGGATC
TGGGTATTTTTCTGGATATGTATGCCTTTGATAACGTGGCCGATGATGAAAAT
GCATATCGTAAACAGGCATGGGATGCATGGTTTTGGGCACATATTCGTATTCT
GATTAGCGTTAGCCATCCGGTTATTCAGGTTCGTGGTTGGCGTGGTCTGCTG
CTGCGTTTTGCATGTGCGGGTGCACATGCCTTTGCACGTATTCTGCGTATTA
GTCCGGAATTTGCCTATCGTAAAGAACGTGAAGCACGTCGTCGTTATGCAAA
TGAAGCGACCAGCCGTATTGGTTATCTGTGTGATACCAATCGTTTTACCCAGA
CCTATGCCTGGGATGATATTAAACCGTTTCTGGACCTGGATTTCGAGGATATG
AAACTGCATTTTCCGCGTGAAATTGATGCAATGCTGCGTGAAATGTTTGGCG
ATTATATGCAGCTGCCTCCGGTTGAAAAACGCAAAAATCATTTTCCGGCACGT
CTGGATTTTGGTGCCTATTAACTCGAG
DNA Sequence: 
MREYDAETLRHVQQCELKILKDVARICDGQGLTYFGLAGTGIGAIRHKGFIPWDDDIDIG
MPARDLEQLVKIIREEHAGTYDVINADIDSNYPLATTRIMLKGTQFCEETLSELPLDLGI
FLDMYAFDNVADDENAYRKQAWDAWFWAHIRILISVSHPVIQVRGWRGLLLRFACAGA
HAFARILRISPEFAYRKEREARRRYANEATSRIGYLCDTNRFTQTYAWDDIKPFLDLDFE
DMKLHFPREIDAMLREMFGDYMQLPPVEKRKNHFPARLDFGAY
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A4. PCR Conditions 
A5. PCR Conditions with a set temperature
A6. TAE Buffer Preparation
To make the 25X TAE stock solution: 
-  Add 141g of Tris base, 28.55 mL glacial acetic acid and 9.3g of EDTA to about 
900mL of  
distilled water 
-  Adjust to 1L with additional distilled water 
To make the 1X TAE buffer used in the gel electrophoresis apparatus: 
-  Add 40mL of the 10X TAE buffer stock to a glass container 
-  Fill the glass container up to 1L with distilled water  
Step Temperature (C) Time (min:sec)
1 94 2:00
2 94 0:15
3 Gradient 50-65 0:10
4 72 1:10, return to step 2*30
5 72 5:00
6 4 Infinite hold
Step Temperature (C) Time (min:sec)
1 94 2:00
2 94 0:15
3 Desired temperature (eg 65) 0:10
4 72 1:10, return to step 2*30
5 72 5:00
6 4 Infinite hold
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A7. Competent cell protocol
 -Streak a glycerol freezer stock of E.coli DH5α or BL21 onto LB-agar plates and grow 
overnight at 37oC 
-  A single colony was picked and used to inoculate 50mL of LB 
-  Culture allowed to grow at 37 oC until OD600 reached approximately 0.5 
-  The culture was transferred to 2 ice-cold sterile 50mL conical tubes which were left 
to sit for 10 minutes 
-  The cultures were then centrifuged at 4oC for 10 min at 2700xg 
-  Supernatant was poured off and the cells were resuspended in 10 mL of 0.1mM ice-
cold CaCl2 
-  Samples were centrifuged once more using the previous two steps 
-  Supernatant was poured off and the pellets were resuspended in 2mL of 0.1mM 
CaCl2 with 15% (w/w) glycerol 
-  The solution was dispensed into 150 uL aliquots 
-  The aliquots were flash frozen using liquid nitrogen and stored at -80oC 
A8. LB and LB-agar 
Preparation of LB media: 
-  Add 2.5 g of LB broth to a glass jar 
-  Top up to 100mL with distilled water
-  Autoclave
Preparation of LB-agar: 
-  Add 2.5g of LB broth to a glass jar 
-  Add 1.5g of agar 
-  Top up to 100mL with distilled water 
-  Autoclave  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A9. Preparation of pET29 extracts for ligation 
-  Streak glycerol freezer stock of pET29 sghf onto LB-agar plates 
-  Incubate at 37oC overnight 
-  Pick a single colony into 3 mL and allow to grow at 37oC in LB media with kanamycin 
overnight
-  Mini-prep the culture
 - Perform a restriction digest of the resulting DNA sample and run on a gel 
 - Cut out the top pET29 band (about 5 kb) 
-  Perform a gel extract  
 A10. Phosphate Buffers for Purification 
Cell Lysis:  50 mM NaPO4 + 300 mM NaCl pH 7.4
- Add 900 mL of Milli-Q water to beaker
- Add 3.87 mL of 1M Na2HPO4
- Add 1.13 mL of 1M NaH2PO4
- Add 17.53 g of NaCl
- Adjust pH to 7.4 with HCl
- Top up to 1L with Milli-Q water
Wash Buffer:  50 mM NaPO4, 20 mM imidazole pH 7.4
- Add 200 mL of Milli-Q water to beaker
- Add 0.97 mL of 1 M Na2HPO4
- Add 0.28 mL of 1M NaH2PO4
- Add 0.34 g of imidazole 
- Adjust pH to 7.4 with HCl
- Top up to 250 mL with Milli-Q water
Elution Buffer: 50 mM NaPO4, 250 mM imidazole pH 7.4
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- Add 200 mL of Milli-Q water to beaker
- Add 0.97 mL of 1 M Na2HPO4
- Add 0.28 mL of 1M NaH2PO4
- Add 4.25 g of imidazole 
- Adjust pH to 7.4 with HCl
- Top up to 250 mL with Milli-Q water
Desalting Buffer: 50 mM NaPO4 pH 8
- Add 900 mL of Milli-Q water to beaker
- Add 3.87 mL of 1M Na2HPO4
- Add 1.13 mL of 1M NaH2PO4
- Adjust pH to 8
- Top up to 1L with Milli-Q water
A11. Tris Buffers for Purification (DTT+AmSO4) 
Cell Lysis: 10 mM Tris, 100 mM NaCl, 2 mM DTT pH 7.5
- Add 80 mL of Milli-Q water to beaker
- Add 0.121 g Tris
- Add 0.584 g NaCl
- Add 0.031 g DTT
- Adjust pH with HCl to 7.5
- Top to 100 mL with Milli-Q water
Wash Buffer: 10 mM Tris, 0.02 M imidazole pH 7.5
- Add 80 mL of Milli-Q water to beaker
- Add 0.121 g Tris
- Add 0.136 g imidazole
- Adjust pH with HCl to 7.5
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- Top to 100 mL with Milli-Q water
Elution Buffer: 10 mM Tris, 0.25 M imidazole pH 7.5
- Add 80 mL of Milli-Q water to beaker
- Add 0.121 g Tris
- Add 1.70 g imidazole
- Adjust pH with HCl to 7.5
- Top to 100 mL with Milli-Q water
Desalting Buffer: 10 mM Tris, 100 mM NaCl, 2 mM DTT and 25% (1M) AmSO4
- Add 80 mL of Milli-Q water to beaker
-  Add 0.121 g Tris
- Add 0.584 g NaCl
- Add 0.031 g DTT
- Add 13.21 g of AmSO4
- Adjust pH with HCl to 7.5
- Top to 100 mL with Milli-Q water
A12. FPLC Buffers
Buffer A: 
-  Add 1.211g of tris to a beaker 
-  Add 400mL of Milli-Q water 
-  Adjust the pH with HCl to 7.5 
- Top up to 500 mL with Milli-Q water  
Buffer B:
-  Add 0.6055g Tris to a beaker 
-  Add 14.39g of NaCl 
-  Add about 200 mL of Milli-Q water 
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-  Adjust the pH to 7.5 using HCl 
-  Top up to 250 mL with Milli-Q water  
A13. SDS PAGE Buffer
Preparation of SDS 10X Running Buffer: 
-  Add 144g glycine to a flask 
-  Add 30.2g Tris base 
-  Dissolve together in 800mL of distilled water 
- Add 10g SDS and mix 
- Top up to 1L with Milli-Q water
Preparation of SDS 1X Running Buffer: 
-  Add 100mL of the 10X stock SDS buffer to a 1L glass container 
-  Top up to 1L with Milli-Q water  
A14. Bradford Reagent
To prepare 250mL of Bradford reagent: 
-  Add 25 mg of Coomassie blue to a beaker 
-  Add 12.5% mL of 95% ethanol 
-  Add 25 mL of phosphoric acid 
-  Top up to 250mL with Milli-Q water 
A15. Bradford assay controls to create the standard curve
BSA (bovine serum albumin) = control protein at concentration of 2 mg/mL 
- Vial 1- 0 ug BSA (reference for the spec)
- Vial 2- 0 ug BSA
- Vial 3- 10 ug BSA
- Vial 4- 20 ug BSA
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- Vial 5- 30 ug BSA
- Vial 6- 40 ug BSA 
- Sample vials contained 5 ng of sample
- All vials were topped up to 100 mL with sterile water
- 5mL of Bradford reagent was then added to each vial
- Let sit for about 5 minutes
- Take an absorbance reading at OD595 for each cuvette and create a standard curve 
A16. Chelax Protocol
- Make 100 mM of Phosphocholine in 10 mL of Milli-Q water
- Make Chelax resin
- 2.68 g of chelax in 6.58 mL of Milli-Q water
- Add resin to column and allow to run through
- Add 10 mL of phosphocholine to the column, and collect the flow through
- Add 0.5 g of addition Chelax to the flow-through collect and stir gently for 1 hour
- After 1 hour, filter the sample and aliquot into small portions
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